Prevention by aging or by cytochalasin B of phalloidin stimulated formation of microfilaments in cell membrane preparations of rat liver

Summary The increased occurrence of microfilaments in cell membrane preparations of rat liver poisoned with phalloidin in vitro was shown to be dependent on the age of the preparations. Cytochalasin B inhibits the formation of microfilaments stimulated by pahlloidin.     

A review of methods to trace material flows into final products in dynamic material flow analysis: Comparative application of six methods to the United States and EXIOBASE3 regions,Part 2

Modeling pathways toward sustainable production and consumption requires improved spatio-temporal and material coverage of end-use product stocks. Momentarily, studies on inflow-driven, dynamic material flow analysis (dMFA) extrapolate scarce information on material end-use shares (i.e., ratios that split economy-wide material consumption to different end-use products) for single countries and years across longer time periods and global regions. Therefore, in part 1 of this work, we reviewed five methods to derive material end-use shares which use industry shipment data in physical units and monetary input–output tables (MIOTs). Herein, we comparatively apply these methods to the United States, drawing on detailed national data, as well as the multi-regional input–output model EXIOBASE3. To better match MIOT and dMFA system definitions, we propose the end-use transfer method, which re-routes specific intermediate outputs to final demand in MIOTs. In closing, we conclude on 12 points for improved end-use shares. We find mixed results regarding the fit between end-use shares derived from industry shipments and MIOTs: for detailed national data, we find good fit for some materials (e.g., aluminum), while others deviate strongly (e.g., steel). In many cases, the temporal trend of MIOT-derived end-use shares roughly agrees with industry shipments. For EXIOBASE3, we find good fit for some countries and materials, but substantial mismatches for others. Despite mixed results, combining MIOT-based end-use shares with industry shipments and auxiliary country-level data could enable improved temporal, geographical, and end-use resolution. However, the scarcity, documentation, and quality of input data are key limitations for more accurate and detailed end-use shares. This article met the requirements for a gold-gold data openness badge described at http://jie.click/badges .      

Cell-free protein synthesis in heart and skeletal muscles from polymyopathic hamsters

1. Cell-free protein synthesis was studied in striated and smooth muscles in an attempt to elucidate the primary genetic defect in polymyopathic hamsters. 2. When washed membrane-free polyribosomes from myopathic and control heart muscle were individually recombined with pH5 enzymes from both types of animals, the pH5 enzymes from myopathic muscle were less active in polypeptide synthesis than those from controls, irrespective of the source of polyribosomes. 3. The same defect was present in skeletal-muscle preparations. 4. Both the initial rate and the maximum extent of incorporation were affected in the defective preparations from myopathic muscle. 5. Concentration differences, with respect to total protein and RNA, were not responsible. 6. Preincubation of the pH5 enzymes resulted in a greater degree of inhibition. 7. The defect in the pH5 enzymes from myopathic muscle was also expressed in poly(U)-directed polyphenylalanine synthesis. 8. Acid proteinase activity in extracts of control and myopathic muscle was the same but general ribonuclease activity in the latter extracts was higher. 9. The defect was also present when both types of pH5 enzymes were prepared in the presence of the ribonuclease-asborbent bentonite. 10. pH5 enzymes from uterine smooth muscle, brains and livers of myopathic animals were similarly affected in homologous and heterologous combinations. 11. It is concluded that the general tissue defect is both qualitative and quantitative in nature, implying that there is a shortage of some essential soluble component in the pH5 fraction which is accompanied by the presence of an altered substituent. This prevents the attainment of extents of polypeptide synthesis in vitro obtained in control extracts from unaffected animals.     

Molecular characterization and module composition of P22-related Salmonella phage genomes.

Genomes of newly isolated Salmonella phages were analysed by comparison of their EcoRI restriction patterns and by hybridization. Characteristic hybridization probes from reference phages P22, ES18 and E. coli phage lambda were chosen. Four probes selected from the lysis region examined the dispersal of the lambdoid lysis genes. Other probes characterized were the replication genes and part of the structural genes. The complex immunity region was investigated by means of hybridization as well as biological tests. The results showed the relationship of the isolated phages to the P22 branch of the lambdoid phages and revealed their modular genome organization consisting of different proportions of P22-related sequences. DNA restriction patterns of phages released from Salmonella strains sampled in limited geographical areas were significantly less heterogeneous than those of phages released from the worldwide sampled SARA collection. The use of prophage restriction patterns as a tool for the typing of Salmonellae to support the epidemiologic classification of pathogenic strains is discussed.     

Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.

Fourteen patients with advanced neuroblastoma, which was unresponsive to or had relapsed despite conventional therapy, were entered into a phase I/II trial of [131I]metaiodobenzylguanidine (131I-MIBG). Doses ranged from 1.85-8.14 GBq each (50-220 mCi), with cumulative doses of 1.85-24.20 GBq (50-654 mCi) in one to three doses. Side effects included mild nausea and vomiting and moderate myelosuppression which occurred in nine patients. Subjective responses occurred in five patients. Four patients had objective responses (one partial, two minor and one mixed). Two of these patients remain alive 80 and 60 months after beginning 131I-MIBG therapy. Comparison of the 131I-MIBG treated patients with 11 carefully matched control patients treated with an advanced current chemotherapy protocol (CCG 8605) was performed by means of Kaplan-Meier life table analysis. The 14% four-year survival with 131I-MIBG compared favorably with the 6% achieved by salvage chemotherapy. We thus believe 131I-MIBG may have a role in the management of neuroblastoma.